Micrographic Surgery & Dermatologic Oncology (Mohs Surgery) — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-26.

Also called: Mohs, MSDO, micrographic surgery, procedural dermatology. A 1-year fellowship entered after a dermatology residency, not a residency you match into from medical school. Organ system: skin, specifically the surgical treatment of skin cancer, the most common cancer in the US.

Subspecialty fellowship of Dermatology.

The 30-second version

Mohs surgery is dermatology's cancer surgery, the one corner of the field where you are the surgeon, the pathologist, and the reconstructive artist in a single afternoon. When a skin cancer sits somewhere the tissue can't be wasted, whether the nose, an eyelid, a lip, or an ear, the Mohs surgeon numbs it, cuts a thin layer, and then, instead of sending it off and waiting days, walks to a microscope in the same suite and reads their own frozen-section margins right there. Tumor left at an edge? They map exactly where on the patient it is and take another sliver, only there, and check again, a loop of cut → read → cut that clears the cancer with near-total margin control (cure rates up to ~99%) while sparing the most healthy skin. Then the same person rebuilds the hole with a flap or a graft and the patient goes home cured, all before dinner. The trade at the center of the field: it keeps almost everything premeds love about dermatology, from outpatient daytime work with essentially no overnight call to low burnout and top-of-medicine pay, in exchange for a more procedural, sometimes repetitive day, real surgical ergonomics, and an entry gauntlet that is brutal twice (you first win one of the hardest residency matches in medicine, then win its single most competitive fellowship).

Quick dashboard (details and sources below)
Training after med school 5 years (1 intern year + 3 yr dermatology + 1 yr Mohs fellowship)
Total from college start ~13 years (4 undergrad + 4 med school + 4 derm training + 1 fellowship)
Training chain Med school (4) → intern year → Dermatology (3 yr) → 1 yr Mohs (MSDO) fellowship
Competitiveness (as a Micrographic Surgery & Dermatologic Oncology fellowship) High — the most sought-after derm fellowship; most who apply broadly match somewhere, but top programs are intense and it's gated behind derm ⟳
Typical full-time pay No survey isolates Mohs. One self-reported figure exists: $710,000 (Physician Side Gigs, 73 dermatologist self-reports, Mohs subset unpublished, 2023–24) ⟳
Pay vs. parent (general dermatology) Higher, by 35% inside that same self-reported pool. Dermatology itself runs $448,000 (Medscape 2026) to $508,401 (Doximity 2025) ⟳
Lifestyle Outpatient, daytime, minimal call — inherits derm's controllability, tilted to a busy procedural day
Burnout No Mohs-specific figure; inherit derm — 31.5% on AMA 2025 against a 41.9% all-physician average ⟳
% women Mohs fellows 50.5% (ACGME, AY2024-25: 49 of 97); incoming fellows ~42% in 2021; parent derm 53% practicing, 65.3% of residents ⟳
DO / IMG accessibility Very low — gated behind derm (~7% DO of positions, near-zero IMG) ⟳

What they actually do

Mohs surgeons remove skin cancer with a tissue-sparing technique built around real-time margin control. The bread and butter is basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) and, at some centers, select melanoma and rarer tumors handled via "slow Mohs" or staged excision, especially when the cancer sits on cosmetically or functionally critical areas (nose, eyelid, ear, lip, hand, genitalia) where every millimeter of healthy tissue matters.12 The defining move: in one same-day outpatient visit, the surgeon numbs the area with local anesthetic, excises a thin layer, and then, acting as both surgeon and pathologist, freezes, sections, stains, and reads ~100% of the deep and peripheral margins under the microscope while the patient waits. If tumor remains at a margin, they map precisely where it is on the patient and take another targeted layer only there, repeating until margins are clear.2

That closed-loop, examine-everything approach is why Mohs achieves cure rates up to ~99% for many skin cancers while removing the least normal skin. Once the margin is clean, the same surgeon usually reconstructs the defect with a primary closure, a local skin flap (advancement, rotation, transposition), or a full- or split-thickness graft, often rebuilding a nose or eyelid with genuine craft. It is procedural, outpatient, awake-patient surgery with an immediate, definitive result: the cancer is out and the margin confirmed before the patient leaves.12

Representative procedures and hands-on work: Mohs micrographic excision with real-time frozen-section margin mapping (the signature procedure) · reading one's own frozen sections at the microscope (surgeon = pathologist) · reconstruction, covering primary and linear closures, local flaps, skin grafts, wedge repairs, and interpolated flaps (e.g., paramedian forehead flap for a nasal defect) · "slow Mohs" or staged excision with permanent sections for melanoma and lentigo maligna at some centers · management of high-risk and recurrent facial/acral tumors.12

A day in the life: structured and rhythmic rather than chaotic. The surgeon opens a board of scheduled patients (often 8–15+ cases). For each: greet and consent, inject local, excise the first Mohs layer, hand the tissue to the histotech who freezes, sections, and stains it (~20–45 min). While that processes, the surgeon rotates to the next patient's excision or reconstruction, then circles back to read their own slides. Clear margin → reconstruct (suture, design a flap/graft) or send home; positive margin → map it and take another targeted layer. The day is a continuous loop of cut → read → reconstruct, several patients in flight at once, wrapping in the late afternoon. One texture: it can feel like "almost the same surgery many times a day": high volume, high repetition, with the real variety (and craft) living in the reconstruction. Essentially no overnight call; the surgeon carries a pager for post-op questions (bleeding, wound care), but true after-hours emergencies are rare, and one experienced Mohs surgeon online put it at roughly 10 call-ins per 10,000 cases.3

The training path & time to completion

Medical school (4 yrs) → 1 intern year → dermatology residency (3 yrs, PGY-2–PGY-4) → 1-year ACGME Mohs (MSDO) fellowship (PGY-5) → board-eligible for ABD subspecialty certification in Micrographic Dermatologic Surgery (MDS).14

  • It's a fellowship two selection gates deep rather than a match-from-med-school residency. You must first complete a full ACGME dermatology residency and be a board-eligible/certified dermatologist. And derm itself has a quirk: most derm spots are "advanced" (PGY-2 start), so the intern year is matched separately (a transitional year or a prelim year in IM, surgery, and so on); see the parent dermatology profile.1
  • Fellowship length: 1 year (12 months), ACGME-accredited, running July–June. A small number of programs add a research year, but one year is the standard.14
  • Single entry route. Unlike some acute fellowships that accept multiple boards, MSDO has exactly one feeder: ACGME dermatology. There is no non-derm path in.1
  • Accreditation and board, and get the history right (a common anchor error): the fellowship has been ACGME-accredited since 2003 (originally as a 1-year Procedural Dermatology fellowship) and was renamed "Micrographic Surgery & Dermatologic Oncology (MSDO)" in 2014.1 What arrived around 2020 is the board certification rather than the accreditation: ABMS approved a Micrographic Dermatologic Surgery (MDS) subspecialty certificate on October 26, 2018, and the American Board of Dermatology (ABD) held its first MDS certification exam ~2020, with 10-year time-limited certification. So: fellowship accreditation = 2003/2014; formal subspecialty certification = ~2020, a genuinely new credential.5 (The osteopathic route, AOBD, also offers a Mohs subspecialty certification.)6
  • Is the fellowship, or the board cert, required to do Mohs? No, and this is an honest nuance. A general dermatologist can legally perform Mohs, and some do (historically via non-ACGME training or self-teaching), and the MDS board exam is voluntary (no penalty for practicing without it). But ACGME fellowship completion is now the recognized, credentialing-friendly, insurer- and hospital-preferred standard, and it's required for membership in the American College of Mohs Surgery (ACMS), the field's main quality signal. It is effectively required for academic Mohs jobs, high-volume referral practices, and being called "fellowship-trained."57
  • Total from the start of college: ~13 years (4 + 4 + 1 intern + 3 derm + 1 Mohs). General dermatology is ~12 years; Mohs adds the single fellowship year.1

The match is distinctive, and it's NOT the NRMP. The MSDO fellowship match runs through the San Francisco (SF) Match with a central application service, coordinated with the ACMS: registration opens ~June, interviews in the fall, match results in December for the following July start.7 One controversial wrinkle: a match-exemption mechanism lets some programs fill positions (often with their own residents) outside the match, a live fairness debate in the field (see Culture).89

How competitive is it?

Mohs is highly competitive, but the story needs the kind-realism nuance, because "competitive fellowship" here means something different from a residency match where most applicants go unmatched.

The single hardest filter is upstream: you must first win a dermatology residency spot, which is cycle after cycle one of the very hardest matches in all of medicine (~99.8% filled, matched US-MD-senior mean Step 2 CK ≈ 257, ~28 abstracts/publications, near-closed to DO and IMG; see the parent dermatology profile).10 By the time you're a dermatology resident, you've already cleared the brutal gate.

Among derm residents, Mohs is the most sought-after fellowship, and the field has genuinely tightened over decades:

  • Programs and positions (2024 SF Match): 79 participating programs offered 96 positions (1–3 each; 64 programs offered one, 13 offered two, 2 offered three). Roughly ~90 ACGME-accredited MSDO programs exist nationally; not all offer a spot every cycle. ⟳11
  • The applicant count is easy to misread. ACMS lists "total applicants ranked" summed across programs at ~1,025 (2024), but that's a sum of rank-list slots, heavily double-counted, since most applicants are ranked by many programs (averaging ~13 ranked applicants per program). It is not a count of unique applicants, and it does not mean ~10 applicants per seat. ⟳11
  • The long-run trend documents the tightening: applicants rose ~34% from 2005→2018 against only a modest rise in positions; measured match success fell from ~66% (2005) to ~61% (2018). Going further back, the field grew from 25 programs/positions in 1995 to 39 in 2000 while the unmatched pool grew sharply. ⟳1213

The honest read (kind realism): because the ~96 positions now roughly track the number of serious applicants, the overall "did I match somewhere" rate is high relative to the derm-residency gauntlet itself, and most residents who apply broadly do land a spot. What's intensely competitive is the specific program you want: top academic programs (MD Anderson, UT Southwestern, Baylor are among the most-ranked) are a genuine scramble, and there's real jockeying on research output, away rotations, and, pointedly, internal-candidate advantage. Post-COVID analyses flag a documented rise in "internal" matches (fellows matching at their home residency program), a fairness/access wrinkle the community talks about openly. So the fair framing is: "competitive for the program you want, and connection-sensitive" rather than "most applicants go unmatched." ⟳89

Board: ABD subspecialty certification in Micrographic Dermatologic Surgery (MDS), first exam ~2020, voluntary and 10-year time-limited.5

Compensation — the robust version

Mohs is the rare fellowship that appears to pay up rather than flat, and the evidence for that is thinner than the claim usually sounds. No compensation survey isolates Mohs. Medscape and Doximity both stop at "dermatology." The American College of Mohs Surgery and the American Society for Dermatologic Surgery each survey their members, but neither posts a compensation report publicly; ACMS's public survey page is about distributing other people's questionnaires to members, and ASDS publishes procedure volumes.14

The parent field, from the two surveys that do exist. Dermatology runs $448,000 on Medscape 2026 (2025 earnings) and $508,401 on Doximity 2025 (2024 earnings, ~37,000 US physicians). The two disagree by about 13% on the same specialty, which is a methodological difference rather than an error in either, so quote one and name it.15 ⟳

The one publicly posted Mohs figure, and what it rests on. Physician Side Gigs runs a self-reported physician salary survey through its own online communities. Its dermatologist page reports $710,000 for full-time Mohs surgeons and calls that 35% higher than its own full-time average across all of dermatology. The whole dermatology sample is 73 data points, gathered between mid-2023 and mid-2024, and the Mohs subset is some unstated fraction of those 73. Physician Side Gigs says so itself: the data is "subject to self-reporting errors and availability of relevant data points from our online communities."14 ⟳

Read that carefully, because it is the number every other site copies. It is one community's self-reports, not a survey with a sampling frame, and self-reported pay skews toward high earners, private practice, and owners rather than employees, and people mix up salary, total compensation, and collections. The 35% comparison is internally consistent, since both halves come from the same pool, so it is the more usable of the two claims. Comparing $710,000 against Medscape's or Doximity's dermatology figure is not valid arithmetic, because those are different samples measured different ways, and doing it is how this page previously ended up asserting a 35% premium that its own numbers put nearer 40–58%.

The mechanism is real even where the salary data is not. Medicare's own claims data shows it. In a 2013 analysis of the Medicare Provider Utilization and Payment file, dermatologists who performed Mohs received an average of $475,884 in total procedure-related Medicare payments that year against $144,565 for dermatologists who did not, and Mohs surgeons made up 71.3% of the top decile of dermatologists by total Medicare reimbursement.16 That is gross payment from one payer before any overhead, so it is emphatically not income. What it establishes is the direction and roughly the scale of the revenue difference, from a public data source rather than a self-report. A Mohs surgeon runs many multi-stage cases a day and separately bills the reconstruction, and the work is medically necessary, insurance-covered skin-cancer care, so it is driven by volume and payer mix rather than by the cash aesthetic market that lifts general dermatology's top end.15

Setting & geography (inherits the derm pattern): private/solo & owner-partner ≫ hospital-employed > academic (academic Mohs the lowest). Higher pay clusters in lower-density Midwest/South markets (shortage premium), while high-density coastal metros pay less base; rural/underserved carries a base-pay shortage premium.15 ⟳

The trade against the parent field. General dermatology already pays $448,000 to $508,401 depending on which survey you read, with no fellowship required. The Mohs year delays attending income by twelve months to reach what looks like a materially higher ceiling, a strong return if you want the surgery, and a real trade-off if you'd be equally happy in general derm.15

The long-run risk to the payoff is reimbursement. Mohs economics ride on Medicare CPT codes that face periodic scrutiny ("appropriate use criteria," fee cuts) and on avoiding oversupply of fellowship-trained surgeons in desirable metros. The premium is robust today but is not guaranteed to be permanent, and the community watches this closely (see Culture).3

What this page removed and why, so you can judge it: it used to carry a FastRVU split of ~$580k–$680k for Mohs against ~$420k–$480k for general dermatology, presented as MGMA- and Medscape-derived. FastRVU republishes figures it cannot link to their source, MGMA's per-specialty tables are paywalled, and neither MGMA nor Medscape publishes a Mohs line at all. Nothing replaced it, because nothing exists to replace it with. ⟳

Lifestyle

Mohs keeps almost all of dermatology's lifestyle advantages, and derm is the "D" in the ROAD-to-lifestyle mnemonic, rated 5/5 on the parent page. The difference is texture rather than schedule: your week looks like a controllable outpatient dermatologist's, tilted toward a busy, hands-on procedural day.3

  • Hours: typically ~4–4.5 clinic/surgery days per week, daytime (roughly 7:30 AM–4 PM), many surgeons taking a half- or full day off, broadly in derm's low ~35–45 hr/week band.3
  • Call is the standout advantage: no overnight or weekend hospital call. A pager for post-op questions (bleeding, wound care) is the only tether, and genuine after-hours emergencies are rare (that ~10-in-10,000 figure again). This is a huge quality-of-life edge over surgical fields with real call.3
  • Setting and control: outpatient, appointment-driven, highly controllable and predictable, so you build your own surgical schedule, take vacation, and can go part-time (financially viable given high per-case revenue).3

The asterisk (why it's a 5 with a caveat, not a frictionless 5). Two honest deductions, and they're about the nature of the work, not the schedule:

  • Procedural repetition. A high volume of similar excisions and closures. Some find it monotonous where general derm offers more case variety; the counter is that reconstruction varies enormously and is where the craft lives.
  • Surgical ergonomics. Hours bent over the microscope and the operating field drive real neck, back, and hand strain over a career. It's controllable, but it's surgery on a treadmill, not clinic.3

Lifestyle rating: 5/5. Top-tier controllability (daytime, outpatient, minimal call, part-time-viable), the same headline as parent dermatology; the only deductions are procedural repetitiveness and surgical ergonomics rather than any schedule burden.

Wellbeing — the part to take seriously

The honest note up front: no clean Mohs-specific wellbeing figures exist, so this section inherits dermatology (well-documented) and adds the one axis Mohs changes.

Burnout inherits derm, which is near the bottom — on one survey, and mid-table on the other. The AMA's 2025 Organizational Biopsy puts dermatology at 31.5% against a 41.9% all-physician average, fifth-lowest of the specialties it names, behind infectious diseases (23.3%), ophthalmology (25.8%), pathology (28.3%) and nephrology (29.3%). Medscape's 2024 report, a different instrument with a higher baseline, lists the ten highest and ten lowest and puts dermatology in neither, so somewhere between 45% and 50% against a 49% average. Both say below average; they disagree on how far. No stand-alone "Mohs burnout %" is published, so treat the exact number as ⟳ verify.10 Mohs plausibly tracks or even beats general derm on acute-stress (no crashing patients, no overnight call, a definitive same-day cure), while adding a physical/ergonomic strain axis general clinic derm doesn't have.3

Happiness inherits derm, near the top. This page used to say dermatology sits at or near the top of "would choose the specialty again," at about 96%. That figure is gone, because nobody publishes a would-choose-again rate by specialty and nobody has since roughly 2019. There is no current number to inherit and none is asserted here. What Medscape does still publish is a different question, whether doctors in a field can be happy and well-balanced, and dermatology ranks high on it at about 87% in the 2025 report. Procedural dermatologists report high satisfaction, and the named drivers are immediate, definitive, curative results and strong autonomy.10

The distinctive emotional profile. Mohs is one of the more emotionally sustainable corners of oncology-adjacent medicine: you treat cancer, but it's usually a curable cancer, removed and confirmed in a single visit, with the patient walking out reconstructed and reassured. That "definitive cure, same day" gratification is a real, repeatable positive, closer to a good-news clinic than to the heavy loss carried in many oncology fields.2

Career longevity is a genuine strength, with one physical caveat. Low acute stress, no overnight call, and easy tapering to part-time make Mohs one of the more sustainable careers into later life. The limiter is musculoskeletal rather than burnout: cumulative neck, back, and hand strain from years at the microscope and operating field. Ergonomics and case-volume management rather than emotional exhaustion are the real longevity levers here.3

Who's in the field (demographics)

Fellowship-specific demographic data is sparse but, unusually, a few dedicated Mohs studies exist, so this is better-sourced than most subspecialties. Where Mohs-specific figures are missing, parent-derm reference data is the best available.

  • Women: at fellow level the gap has closed. ACGME counted 97 Mohs fellows in academic year 2024-25, 49 of them women, or 50.5%.10 The trend behind that figure: incoming Mohs fellows went from ~24% women (1996) to ~42% (2021), with a significant positive year-trend that 2010–2024 work shows continuing toward roughly half.1718 For context, parent general dermatology is 53% women practicing (AAMC, 2022 data) and 65.3% of residents (ACGME, AY2024-25).10 The read: Mohs, as a procedural subspecialty, is perceived to skew somewhat more male than outpatient derm overall, and at fellow level the count no longer supports that perception. Program-director ranks lag further (~3% women in 1996 → ~28% in 2022, still male-majority but improving).17 ⟳
  • DO: low. No fellowship-specific figure exists, but Mohs is drawn almost entirely from US-MD dermatologists because the parent field is among the least DO-friendly (~7% of derm positions go to DOs). An osteopathic Mohs certification pathway (AOBD) exists, but the DO share of the Mohs workforce is small.106 ⟳
  • IMG: very low, near-zero, inherited from derm being among the least IMG-friendly specialties (near-zero IMG entry). No fellowship-specific breakdown exists.10 ⟳
  • Race and ethnicity: one of the least diverse corners of medicine. Mohs inherits dermatology's status as one of the least racially diverse specialties (parent field: Black ~4.6%, Hispanic or Latinx ~6.6% of dermatologists). Dedicated Mohs-fellow diversity studies document low URiM representation among fellows and program directors, with slow improvement, consistent with and downstream of the derm-residency diversity gap. Treat exact Mohs-fellow URiM percentages as limited data and cite the parent-field figures.1910 ⟳

Culture, personality & the online stereotypes

Who gravitates here: dermatologists who fell in love with the procedural and surgical side of residency, people who like working with their hands, precise margin-controlled cutting, and especially reconstruction as craft (designing a flap to rebuild a nose or an eyelid is genuinely artistic). They tend to be detail-obsessed and comfortable being both the surgeon and the pathologist in the same sitting, and many are drawn by the immediate, definitive cure of tumor out, margin confirmed, patient reconstructed, all in one visit, over the longitudinal management of general derm. It also self-selects for very high academic achievers, because you have to be a competitive dermatology resident first and then win the field's most competitive fellowship. As always, plenty of people in the field don't fit any single mold.

The stereotypes. Community perception rather than fact. Each carries a kernel and an unfair edge, and plenty of people do not fit the mold:

  • "The surgeons of dermatology." The read online is that Mohs people are the ones who wanted to operate: more OR-minded, more procedural, a little more "surgeon" in temperament than the average derm. Kernel of truth, but it's outpatient awake surgery, the day still has plenty of clinic-like flow, and it's not a surgical-personality caricature.
  • "The derm within derm: highest-paid, most competitive." The perception that Mohs is where the top-of-the-class, most driven derm residents funnel for money and prestige. Real pattern (it is the top-earning, hardest derm fellowship), but it flattens the genuine clinical draw, since many do it because they love the surgery and the cancer-cure mission rather than the paycheck.
  • "Doing the same surgery 14 times a day." A jab at procedural monotony. There's truth to the repetition; the counter is that the reconstruction varies enormously and is where the craft and satisfaction live.
  • "The internal-match club." A pointed, recurring criticism that some programs use match-exemptions to keep their own residents, making the field feel connections- and pedigree-driven and less meritocratic for outside applicants. This one has real data behind it (a documented post-COVID rise in internal matches), so it is a live controversy rather than only a stereotype. It still doesn't describe every program.

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, Mohs is widely treated as the crown-jewel derm fellowship: top-paying, most sought-after, hardest to land. On lifestyle, the consensus is that Mohs sits much closer to derm than to surgery: structured daytime hours, minimal real call (a pager for post-op questions, true emergencies vanishingly rare), and strong control, but a more procedural, higher-volume, sometimes repetitive day than general clinic. On money, posters caution that published salary surveys are skewed and volume-dependent while agreeing Mohs is the top of the derm earnings ladder. Two anxieties dominate the "is it worth it?" threads: (1) the internal-match / exemption controversy, with strong feelings that pedigree and who-you-know tilt selection; and (2) the long-run job market and Medicare pressure, with worry about oversupply of fellowship-trained Mohs surgeons, appropriate-use scrutiny, and reimbursement cuts squeezing the golden-goose economics. A frequently repeated piece of insider advice: never lead with lifestyle or money as your motivation in interviews, because in a field this competitive that reads as a red flag. The overall tone: proud of the craft and the cure, clear-eyed (a little wary) about the politics of getting in and the economics of staying rich.3

Voices from the field. Paraphrased from public writing, with links to the originals:

  • A Cutis/JAAD review, "The Evolution of the MSDO Fellowship," traces how a 1-year procedural-derm fellowship (ACGME 2003, renamed MSDO 2014) matured into a formal ABMS/ABD subspecialty (MDS certification approved 2018, first exam ~2020), and documents applicant growth against a modest rise in positions, the structural reason competitiveness intensified.12
  • A JAAD analysis of the COVID-era Mohs match (comparing 2017–2019 to 2020–2022) and a companion SF Match study document a notable rise in internal matches and a tightening applicant landscape, the empirical backbone of the online "internal-match club" critique.89
  • The American College of Mohs Surgery (ACMS) frames Mohs as the highest-cure, most tissue-sparing treatment for skin cancer and stewards the fellowship match, membership standards, and the (contested) match-exemption policy.72
  • Physician Side Gigs' self-report pool puts full-time Mohs surgeons at $710,000, 35% above its own all-dermatology figure, though the Mohs subset size inside its 73 responses is not published. Medicare's claims data supports the direction independently: dermatologists who performed Mohs collected roughly three and a half times the Medicare payment of those who didn't.1416

Why people choose it / why people leave

Why choose it: the best-paid path in dermatology for one extra year of training, though the only figure anyone publishes for it is self-reported · keeps derm's elite lifestyle, being outpatient, daytime, essentially free of overnight call, part-time-viable, and low burnout · an immediate, definitive cure (tumor removed, ~100% margin confirmed, reconstructed in a single visit; cure rates up to ~99%) · the surgeon + pathologist + reconstructive-artist trifecta in one role, with reconstruction as genuinely creative craft · a mission-clear job (skin cancer is the most common cancer in the US, and Mohs is the gold standard for high-risk/facial tumors) · excellent job security and geographic flexibility (skin cancer is everywhere, concentrated in older and Sun Belt populations).

Why leave or avoid it: procedural repetition, with high-volume, similar cases and less variety than general derm's medical, pediatric, cosmetic, and inflammatory mix · surgical ergonomics, with cumulative neck, back, and hand strain over a career · the entry gauntlet is brutal twice, since you must win the derm match (among the hardest in medicine, near-closed to DO and IMG) and then the single most competitive derm fellowship · internal-match and exemption politics, a real perception (and data) that pedigree and connections tilt selection · reimbursement risk, since economics ride on Medicare Mohs codes under periodic scrutiny · you give up derm's cash-pay cosmetic upside if you go pure-Mohs (though many blend), and do far less longitudinal medical dermatology.

Best fit if: you loved the surgical/procedural rotations of derm residency · you enjoy precise, margin-controlled cutting and reconstructive design · you want a definitive, same-day curative result over longitudinal management · you're a top-tier derm resident willing to run a second competitive gauntlet · you want top derm pay without sacrificing a controllable, call-light life.

Not for you if: you'd be bored by procedural repetition · you want the full breadth of medical/pediatric/cosmetic derm · surgical ergonomics (hours at a microscope) would wear you down · you're not positioned (research, mentorship, home Mohs program) to compete for one of the field's most connection-sensitive fellowships · you'd rather sub-specialize in inflammatory/immunodermatology or dermatopathology.

The FLI angle — Micrographic Surgery & Dermatologic Oncology (Mohs Surgery) for first-gen, low-income & immigrant students

Where it fits FLI realities well:

  • Elite, durable income, and fast. One extra year after derm buys the top earnings tier in a top-paying specialty, on top of a parent field already at $448,000 to $508,401, with a controllable, sustainable life, genuinely family-trajectory-changing financial mobility, reached quickly relative to the multi-year procedural fellowships in other fields (Mohs is only one year).
  • Geographic flexibility. Skin cancer is ubiquitous (and concentrated in older, sun-exposed, Sun Belt populations), so Mohs surgeons can practice near family or in lower-cost areas rather than only academic hubs, real freedom for someone with family or geographic ties.
  • Part-time is financially real. High per-case revenue means dialing back hours later (for caregiving or health) doesn't gut your income.

Risks to name honestly:

  • The access barrier is the whole story, and it's doubled. Mohs sits behind dermatology, which is one of the least DO/IMG-accessible and least racially diverse specialties in all of medicine (~7% DO of positions, near-zero IMG, Black ~4.6% and Hispanic ~6.6% of dermatologists; see the parent page). You cannot reach Mohs without first clearing derm's research/mentorship/away-rotation arms race, which structurally disadvantages FLI applicants without a home derm department or funded research time. Then Mohs adds a second, connection-sensitive selection, and the internal-match and exemption controversy is a documented fairness concern. For an FLI student that's two consecutive gates where resources and pedigree tilt the odds. Name it squarely and plan around it.1910
  • PSLF fits poorly. Mohs is private-practice-heavy (including PE-backed groups), and those employers usually don't qualify for Public Service Loan Forgiveness. Academic Mohs (501(c)(3) hospitals) qualifies but pays less. If loan forgiveness is central to your debt plan, this path leans toward pay-it-down-with-high-income rather than PSLF. Ground it honestly: most physicians carry ~$200k+ in student debt; a high Mohs income services it fast, but PSLF is a weaker lever here than in hospital-based fields.
  • Reimbursement is the long-run risk to the payoff. The economics ride on Medicare Mohs codes; appropriate-use scrutiny and periodic fee cuts are real and could compress the premium over general derm.
  • Earning speed against one more gate. If you need to start earning immediately, general dermatology already pays $448,000 to $508,401 with no fellowship, so the Mohs year is a delay that pays off only if you genuinely want the surgery rather than just the ceiling.

Bottom line for FLI: Mohs is one of the highest-reward endpoints in all of medicine: top derm pay, a controllable life, a one-year fellowship, and a clear curative mission. But it's gated twice by exactly the resources FLI students tend to have least of: research, mentorship, away-rotation money, and connections that matter in a small, pedigree-sensitive match. It's achievable, and the honest plan is to decide early, get into a derm program that has a Mohs fellowship and surgical mentorship, publish in dermatologic surgery, and go in eyes-open about both the access barrier and the reimbursement risk. Choose it because you love the surgery and the cure. The money and lifestyle are real, but they're the byline, not the reason.

Fun facts

  • The surgeon reads their own pathology. Mohs is one of the only fields where a single physician is the surgeon and the pathologist in the same sitting, cutting the tissue and then walking to a microscope to read ~100% of its margins in real time.
  • The technique is named for Dr. Frederic Mohs, who developed it at the University of Wisconsin in the 1930s (originally with a chemical tissue-fixative paste; the modern fresh-tissue frozen-section technique came later).
  • Near-total margin control is the whole point: because Mohs examines essentially the entire peripheral and deep margin, rather than the thin "bread-loaf" samples of standard excision, it reaches cure rates up to ~99% for many skin cancers while sparing the most healthy tissue.
  • The credential is genuinely new. The fellowship has been ACGME-accredited since 2003 (renamed MSDO in 2014), but the formal board certification (ABD's MDS exam) only arrived ~2020, younger than many of the surgeons holding it.
  • It doesn't use the NRMP. The Mohs fellowship matches through the SF Match in December, a separate system with a controversial "match-exemption" mechanism that lets some programs fill outside the match.
  • Unlike much of high-end dermatology's income, Mohs revenue is insurance-covered cancer care rather than cash-pay cosmetics, and the money comes from wRVU-heavy procedures (a Mohs first stage is worth ~8× a skin biopsy) rather than from Botox and fillers.

Sources

Footnotes

  1. Training pathway, prerequisite (ACGME dermatology residency), 1-year ACGME MSDO fellowship, accreditation history (2003 as Procedural Dermatology → renamed MSDO 2014), single entry route, ~13-year total. American Board of Dermatology — MSDO Fellowship Training page, 2026 (https://www.abderm.org/residents-and-fellows/fellowship-training/micrographic-surgery-and-dermatologic-oncology). Consistent with the dermatology profile on this site. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  2. American College of Mohs Surgery — Mohs as the highest-cure (up to ~99%), most tissue-sparing treatment for skin cancer; the surgeon-as-pathologist real-time frozen-section margin technique; reconstruction; mission framing. https://www.mohscollege.org/for-physicians/acms-fellowship-training/for-dermatology-residents and https://www.mohscollege.org (2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. Student Doctor Network forum, "Mohs lifestyle: derm or surg?" — paraphrased community sentiment: ~4–4.5 daytime days/week, pager for post-op only, true emergencies vanishingly rare (~10 call-ins per 10,000 cases), procedural repetition and surgical ergonomics as the real deductions, published salary surveys skewed/volume-dependent, internal-match and Medicare-reimbursement anxieties, "don't lead with lifestyle/money in interviews." https://forums.studentdoctor.net/threads/mohs-lifestyle-derm-or-surg.1009549/ (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  4. ACGME Program Requirements for Graduate Medical Education in Micrographic Surgery and Dermatologic Oncology (2025 reformatted) — 1-year ACGME-accredited fellowship entered after dermatology residency. https://www.acgme.org/globalassets/pfassets/programrequirements/2025-reformatted-requirements/081_micrographicsurgerydermatologiconcology_2025_reformatted.pdf (2025). ↩ ↩2

  5. ABD Micrographic Dermatologic Surgery (MDS) subspecialty certification — ABMS approved the subspecialty Oct 26, 2018; first ABD MDS exam ~2020; voluntary, 10-year time-limited; prerequisites (ABD general derm certification + ACGME MSDO fellowship, with an initial 5-year practice-pathway window). American Board of Dermatology — MDS Q&A (https://dlpgnf31z4a6s.cloudfront.net/media/165774/20018-mds-q-and-a.pdf) and MDS Subspecialty Certification Exam page (https://www.abderm.org/residents-and-fellows). ~2019–2020. ⟳ ↩ ↩2 ↩3

  6. American Osteopathic Board of Dermatology — Mohs Micrographic Surgery subspecialty certification (osteopathic pathway). https://certification.osteopathic.org/dermatology/certification-process/mohs-micrographic-surgery/ (accessed 2026). ↩ ↩2

  7. American College of Mohs Surgery — "For Dermatology Residents" (SF Match process: registration ~June, interviews fall, match December, July start; only ACGME-MSDO fellowship graduates eligible for ACMS membership). https://www.mohscollege.org/for-physicians/acms-fellowship-training/for-dermatology-residents (2026). ↩ ↩2 ↩3

  8. PubMed 38847510, "Internal Matches to Mohs Fellowship Increase After COVID-19" — documented post-COVID rise in fellows matching at their home residency program. https://pubmed.ncbi.nlm.nih.gov/38847510/ (2024). ⟳ ↩ ↩2 ↩3

  9. PubMed 38787440 (Arch Dermatol Res), "Insights into the MSDO Fellowship Match: 2020–2022 SF Match Data" — SF Match analysis of the tightening applicant landscape. https://pubmed.ncbi.nlm.nih.gov/38787440/ (2024). ⟳ ↩ ↩2 ↩3

  10. Cross-specialty figures for parent dermatology. Women in practice, 53%: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america. Women in training: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf, which puts dermatology residents at 65.3% and, three rows below it, micrographic surgery and dermatologic oncology at 84 programs, 97 fellows, 49 women (50.5%) and 48 men (49.5%). Corrected 2026-08-13: this page carried ~51–53% practicing and ~60% of residents. Corrected 2026-08-17: this footnote said the table "carries no Mohs micrographic surgery row," and the row is there and answers the question the dashboard had been calling unanswerable. The fellow-level figure is now stated as 50.5% and the 1996→2021 series is kept as the trend behind it. DO and IMG access: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf, where dermatology offered 546 PGY-2 positions, filled 99.8% of them, and gave 7.3% to DO graduates and 2.4% to international graduates. Burnout: Medscape Physician Burnout & Depression Report 2024, n=9,226, fielded July–October 2023, paywalled and returning HTTP 402, so it reaches this page through two independent relays that agree on the edition, the instrument and every row — Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty) and Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout). Both relays print the ten highest-burnout specialties, from emergency medicine at 63% down to internal medicine at 50%, and the ten lowest, from plastic surgery at 37% up to critical care at 45%. Dermatology is in neither list, so this edition supports a band between 45% and 50% against a 49% all-physician average rather than a point figure. The page's headline burnout number is the AMA 2025 Organizational Biopsy's 31.5% for dermatology against a 41.9% all-physician average, which is primary and free. Corrected 2026-08-17: this footnote asserted a specific 46% for dermatology, which neither named relay prints, and it said the page carried "low-to-mid-30s%" from an unopened edition, which stopped being true when the page moved to AMA 2025. It also said three relays and named two. The dashboard row still read "among the LOWEST of all specialties on Medscape 2024," the claim the body had already retracted, and now carries the AMA figure. Would-choose-again is deleted rather than corrected. No publisher breaks it out by specialty and none has since about 2019, so the ~96% that used to sit here has no source and no replacement. The ~87% is a different Medscape question from the 2025 report, on whether doctors in a field can be happy and well-balanced, and it is named as that. The Step 2 CK ~257, ~28 publications and ~99.8% fill competitiveness figures come from the dermatology profile on this site, which is a cross-reference rather than a source; the 99.8% fill is confirmed by the NRMP report above. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  11. ACMS "2024 Number of Applicants Ranked" — 79 participating programs, 96 positions offered (64 programs offering one, 13 offering two, 2 offering three); ~1,025 total applicant rank-slots summed across programs (a heavily double-counted sum, NOT unique applicants; the PDF's own stated average is 12.97 ranked per program); most-ranked programs UT–MD Anderson (30), UT Southwestern & Baylor (29 each). https://www.mohscollege.org/UserFiles/SISRB/2024No.ofApplicantsRanked.pdf (2024). Corrected 2026-08-17: the position total read 104 here and in two places in the body, including the sentence resting the competitiveness argument on it. Summing the PDF's own Positions Offered column across its 79 program rows gives 96; summing the adjacent Applicants Ranked column over the same rows reproduces the PDF's stated 1,025 exactly, which is the check on the parse. 96 also agrees with the ACGME Data Resource Book AY2024-25, which counts 97 active MSDO fellows in 84 programs. The "roughly track the number of serious applicants" reading survives the smaller total, since the measured match-success series in 12 is what carries it. ⟳ ↩ ↩2

  12. Cutis/JAAD, "The Evolution of the MSDO Fellowship" — ACGME accreditation 2003 (Procedural Dermatology), renamed MSDO 2014, ABMS subspecialty approved Oct 26 2018; ~76 accredited programs; positions 50 (2005) → 58 (2018); applicants +34% 2005→2018; match success 66.2% → 61.1%. https://cdn.mdedge.com/files/s3fs-public/CT103004022_e.PDF (2022). ⟳ ↩ ↩2 ↩3

  13. escholarship, "The Increased Competitiveness of Mohs Micrographic Surgery Training" — 1995: 25 programs/25 positions/43 applicants (~91% match); 2000: 39 programs/39 positions/65 applicants (~72% match); unmatched pool grew as programs grew (dated 1995–2000 baseline). https://escholarship.org/uc/item/7b51c07x. ⟳ ↩

  14. The Mohs self-report figure, and the absence of a society survey. Physician Side Gigs, "Average Dermatologist Salary," https://www.physiciansidegigs.com/average-dermatologist-salary — $710,000 for full-time (31+ hrs/week) dermatologists specializing in Mohs surgery, "35% higher than our full-time average across all specialties in dermatology." Sample: 73 data points for dermatology overall, gathered between mid-2023 and mid-2024; the Mohs subset size is not published. Stated method, verbatim: the data "is derived from our physician salary and compensation databases, but is subject to self-reporting errors and availability of relevant data points from our online communities." Anonymous self-reports contributed through the publisher's own physician communities, so this is community-reported data with a named publisher rather than a survey with a sampling frame. Also on the page: female dermatologists $501,000, male $591,000. Society surveys checked and absent: the American College of Mohs Surgery's public member-surveys page (https://www.mohscollege.org/media/member-surveys) describes how outside researchers distribute questionnaires to its ~1,600 members and posts no results, compensation or otherwise; the American Society for Dermatologic Surgery publishes a consumer survey and a procedures survey (https://www.asds.net/medical-professionals/practice-resources/survey-on-dermatologic-procedures) and no member compensation data. ⟳ ↩ ↩2 ↩3

  15. Dermatology parent-field compensation and practice pattern. Medscape Physician Compensation Report 2026, 2025 earnings — dermatology $448,000. The report is paywalled and returns HTTP 402, so its 29-row table reaches this page through The DO (American Osteopathic Association), which prints the full list: https://thedo.osteopathic.org/2026/07/what-physicians-are-getting-paid-in-2026/ . Doximity 2025 Physician Compensation Report, 2024 earnings — dermatology $508,401, from over 37,000 US physician responses collected during 2024; the report has no Mohs line and no dermatology subspecialty lines: https://www.doximity.com/reports/physician-compensation-report/2025 . Setting/geography pattern (solo/partner ≫ hospital > academic; Midwest/South shortage premium), wRVU-based pay, Mohs as the highest-paid derm subspecialty; the cash-pay-cosmetic vs. insurance-covered-Mohs distinction. 2026. ⟳ ↩ ↩2 ↩3 ↩4

  16. Mohs revenue mechanism, from Medicare claims rather than from self-report. "Mohs Micrographic Surgery Volume and Payment Patterns Among Dermatologists in the Medicare Population, 2013," American Journal of Clinical Oncology, December 2018, PMID 29672366, https://pubmed.ncbi.nlm.nih.gov/29672366/ — dermatologists performing MMS averaged $475,883.64 in total procedure-related Medicare compensation against $144,564.74 for those not performing MMS (r=0.49, P<0.0001); average services per provider 5,419.4 against 3,627.1; MMS-performing dermatologists were 71.3% of the top decile of dermatologists by total Medicare reimbursement. Source data: the CMS Medicare Provider Utilization and Payment Data public use file, 2013. This is gross Medicare Part B fee-for-service payment to the provider, before overhead and excluding every commercial payer. It is not salary and must never be quoted as income. On the gender gap in the same data: "Trends in Gender Representation and Impact of Practice Setting on Productivity and Reimbursement Gap for Female Mohs Micrographic Surgery Physicians," PMID 39589848 — MMS surgeons billing Medicare rose from 2,135 (2013) to 2,605 (2019), female share 28% to 32%. This footnote previously held a FastRVU 2026 page giving Mohs ~$580k–$680k against general dermatology ~$420k–$480k, attributed to MGMA, Medscape and CMS. FastRVU cannot link to the MGMA data it republishes, MGMA's per-specialty tables are paywalled, and neither MGMA nor Medscape publishes a Mohs line. It was removed rather than relabeled, along with the ~$54/wRVU and CPT wRVU figures that reached this page only through it. ⟳ ↩ ↩2

  17. Gender diversity of Mohs fellows and program directors — incoming female fellows ~24% (1996) → ~42% (2021); female program directors ~3% (1996) → ~28% (2022); significant positive trend. Dermsquared / Physicians Weekly summarizing PMC10413217 (https://dermsquared.com/news-research/percentage-of-women-mohs-fellows-program-directors-has-increased) (2023). ⟳ ↩ ↩2

  18. JAAD/ScienceDirect, "Demographic trends for fellows in Mohs surgery and dermatopathology 2010–2024" — continued rise in women fellows toward ~half. https://www.sciencedirect.com/science/article/abs/pii/S0190962225032396 (2025). ⟳ ↩

  19. Racial/ethnic diversity of Mohs fellows and program directors — low URiM representation with slow improvement, downstream of the derm-residency diversity gap (exact Mohs-fellow URiM % = limited data). JAAD International 2021 (https://www.jaadinternational.org/article/S2666-3287(21)00084-5/fulltext); Research Square 2025, "Trends in Racial and Ethnic Diversity Among MSDO Fellows and Directors" (https://www.researchsquare.com/article/rs-8060499/v1). ⟳ ↩ ↩2

Researched with AI assistance and reviewed by hand. How this site is made